Global Cancer / Tumor Profiling Market Overview:
Global Cancer / Tumor Profiling Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Cancer / Tumor Profiling Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Cancer / Tumor Profiling involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Cancer / Tumor Profiling Market:
The Cancer / Tumor Profiling Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Cancer / Tumor Profiling Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Cancer / Tumor Profiling Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Cancer / Tumor Profiling market has been segmented into:
Immunoassays
Next Generation Sequencing
In-Situ Hybridization
Polymerase Chain Reaction
Mass Spectrometry
Other Technologies
By Application, Cancer / Tumor Profiling market has been segmented into:
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Other Cancer Types
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Cancer / Tumor Profiling market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Cancer / Tumor Profiling market.
Top Key Players Covered in Cancer / Tumor Profiling market are:
Agilent Technologies Inc.
Caris Life Sciences
Exact Sciences Corporation
Guardant Health Inc.
Hologic Inc.
Illumina SAPAC
IMB Dx Inc.
Lucence Health Inc.
NeoGenomics Laboratories Inc.
Roche Sequencing Solutions Inc.
Sysmex Corporation
Tempus Labs
Thermo Fisher Scientific Inc.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Cancer / Tumor Profiling Market Type
4.1 Cancer / Tumor Profiling Market Snapshot and Growth Engine
4.2 Cancer / Tumor Profiling Market Overview
4.3 Immunoassays
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Immunoassays: Geographic Segmentation Analysis
4.4 Next Generation Sequencing
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Next Generation Sequencing: Geographic Segmentation Analysis
4.5 In-Situ Hybridization
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 In-Situ Hybridization: Geographic Segmentation Analysis
4.6 Polymerase Chain Reaction
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Polymerase Chain Reaction: Geographic Segmentation Analysis
4.7 Mass Spectrometry
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Mass Spectrometry: Geographic Segmentation Analysis
4.8 Other Technologies
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Other Technologies: Geographic Segmentation Analysis
Chapter 5: Cancer / Tumor Profiling Market Application
5.1 Cancer / Tumor Profiling Market Snapshot and Growth Engine
5.2 Cancer / Tumor Profiling Market Overview
5.3 Breast Cancer
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Breast Cancer: Geographic Segmentation Analysis
5.4 Lung Cancer
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Lung Cancer: Geographic Segmentation Analysis
5.5 Colorectal Cancer
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Colorectal Cancer: Geographic Segmentation Analysis
5.6 Prostate Cancer
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Prostate Cancer: Geographic Segmentation Analysis
5.7 Melanoma Cancer
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Melanoma Cancer: Geographic Segmentation Analysis
5.8 Other Cancer Types
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Other Cancer Types: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Cancer / Tumor Profiling Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 AGILENT TECHNOLOGIES
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC.; CARIS LIFE SCIENCES; EXACT SCIENCES CORPORATION; GUARDANT HEALTH
6.4 INC.; HOLOGIC
6.5 INC.; ILLUMINA SAPAC; IMB DX
6.6 INC.; LUCENCE HEALTH
6.7 INC.; NEOGENOMICS LABORATORIES INC.; ROCHE SEQUENCING SOLUTIONS
6.8 INC.; SYSMEX CORPORATION; TEMPUS LABS; THERMO FISHER SCIENTIFIC INC.
Chapter 7: Global Cancer / Tumor Profiling Market By Region
7.1 Overview
7.2. North America Cancer / Tumor Profiling Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Immunoassays
7.2.2.2 Next Generation Sequencing
7.2.2.3 In-Situ Hybridization
7.2.2.4 Polymerase Chain Reaction
7.2.2.5 Mass Spectrometry
7.2.2.6 Other Technologies
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Breast Cancer
7.2.3.2 Lung Cancer
7.2.3.3 Colorectal Cancer
7.2.3.4 Prostate Cancer
7.2.3.5 Melanoma Cancer
7.2.3.6 Other Cancer Types
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Cancer / Tumor Profiling Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Immunoassays
7.3.2.2 Next Generation Sequencing
7.3.2.3 In-Situ Hybridization
7.3.2.4 Polymerase Chain Reaction
7.3.2.5 Mass Spectrometry
7.3.2.6 Other Technologies
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Breast Cancer
7.3.3.2 Lung Cancer
7.3.3.3 Colorectal Cancer
7.3.3.4 Prostate Cancer
7.3.3.5 Melanoma Cancer
7.3.3.6 Other Cancer Types
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Cancer / Tumor Profiling Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Immunoassays
7.4.2.2 Next Generation Sequencing
7.4.2.3 In-Situ Hybridization
7.4.2.4 Polymerase Chain Reaction
7.4.2.5 Mass Spectrometry
7.4.2.6 Other Technologies
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Breast Cancer
7.4.3.2 Lung Cancer
7.4.3.3 Colorectal Cancer
7.4.3.4 Prostate Cancer
7.4.3.5 Melanoma Cancer
7.4.3.6 Other Cancer Types
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Cancer / Tumor Profiling Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Immunoassays
7.5.2.2 Next Generation Sequencing
7.5.2.3 In-Situ Hybridization
7.5.2.4 Polymerase Chain Reaction
7.5.2.5 Mass Spectrometry
7.5.2.6 Other Technologies
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Breast Cancer
7.5.3.2 Lung Cancer
7.5.3.3 Colorectal Cancer
7.5.3.4 Prostate Cancer
7.5.3.5 Melanoma Cancer
7.5.3.6 Other Cancer Types
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Cancer / Tumor Profiling Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Immunoassays
7.6.2.2 Next Generation Sequencing
7.6.2.3 In-Situ Hybridization
7.6.2.4 Polymerase Chain Reaction
7.6.2.5 Mass Spectrometry
7.6.2.6 Other Technologies
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Breast Cancer
7.6.3.2 Lung Cancer
7.6.3.3 Colorectal Cancer
7.6.3.4 Prostate Cancer
7.6.3.5 Melanoma Cancer
7.6.3.6 Other Cancer Types
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Cancer / Tumor Profiling Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Immunoassays
7.7.2.2 Next Generation Sequencing
7.7.2.3 In-Situ Hybridization
7.7.2.4 Polymerase Chain Reaction
7.7.2.5 Mass Spectrometry
7.7.2.6 Other Technologies
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Breast Cancer
7.7.3.2 Lung Cancer
7.7.3.3 Colorectal Cancer
7.7.3.4 Prostate Cancer
7.7.3.5 Melanoma Cancer
7.7.3.6 Other Cancer Types
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Cancer / Tumor Profiling Scope:
|
Report Data
|
Cancer / Tumor Profiling Market
|
|
Cancer / Tumor Profiling Market Size in 2025
|
USD XX million
|
|
Cancer / Tumor Profiling CAGR 2025 - 2032
|
XX%
|
|
Cancer / Tumor Profiling Base Year
|
2024
|
|
Cancer / Tumor Profiling Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Agilent Technologies Inc., Caris Life Sciences, Exact Sciences Corporation, Guardant Health Inc., Hologic Inc., Illumina SAPAC, IMB Dx Inc., Lucence Health Inc., NeoGenomics Laboratories Inc., Roche Sequencing Solutions Inc., Sysmex Corporation, Tempus Labs, Thermo Fisher Scientific Inc..
|
|
Key Segments
|
By Type
Immunoassays
Next Generation Sequencing
In-Situ Hybridization
Polymerase Chain Reaction
Mass Spectrometry
Other Technologies
By Applications
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Other Cancer Types
|
